No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ATRC240621C30000
- 0.25
- 0.000.00%
15min DelayTrading May 10 09:48 ET
0.00High0.00Low
0.00Open0.25Pre Close0 Volume1 Open Interest30.00Strike Price0.00Turnover295.08%IV31.07%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type0.1211Delta0.0444Gamma92.32Leverage Ratio-0.2306Theta0.0001Rho11.18Eff Leverage0.0031Vega
Intraday
- 5D
- Daily
News
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersMustang Bio (NASDAQ:MBIO) stock moved upwards by 50.0% to $1.12 during Tuesday's regular session. The company's market cap stands at $31.7 million. Sonoma Pharmaceuticals (NASDAQ:SNOA) shares i
Express News | Watching AtriCure; Traders Circulating Unconfirmed Rumor Suggesting Edwards Lifesciences Is Said To Mull Takeover Bid For The Co
AtriCure Gains Amid Report of Edwards Lifesciences Interest
An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 48% Undervalued
Key Insights AtriCure's estimated fair value is US$39.98 based on 2 Stage Free Cash Flow to Equity AtriCure is estimated to be 48% undervalued based on current share price of US$20.97 The US$47.3
Is AtriCure, Inc. (NASDAQ:ATRC) Trading At A 48% Discount?
Insider Buying: Chief Technical Officer Salvatore Privitera Acquires Shares of AtriCure Inc (ATRC)
Comments
Insider transactions at AtriCure are not encouraging. However, insiders' share ownership suggests some alignment. Maggie Yuen's sale at a price above the current share price may not reflect insider confidence.
Investors forecast sustained strong revenue performance from AtriCure, reflected in a high P/S ratio. Shareholders currently show confidence in the company's future revenue, bolstering its shares. The high P/S ratio is deemed appropriate due to robust future revenues.
The lack of insider purchasing and ample selling in the past year could be red flags for potential investors in AtriCure. Despite high insider ownership, absence of buying is unsettling. Additionally, unspecified risks and concerns for AtriCure are noteworthy.
Read more